Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US6323071042
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001J1BQ86
NTRA
Natera Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $PLNG
NAME
Natera Inc
ISIN
US6323071042
TICKER
NTRA
MIC
XNAS
REUTERS
NTRA.OQ
BLOOMBERG
NTRA US
Thu, 11.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study. Presented today at the San Ant...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual Meeting. Real-world Signatera Analysis: Oral Presentation on December 6 A real-world analysis of personalized circulating tumor DNA (ctDN...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company’...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validi...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.12.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12. The presentations encompass aggregated data from more than 50,000 patients in real-world evi...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its employees contributed more than 1,500 volunteer hours during the company’s fourth annual Volunteer Month. This initiative takes place each October and is organized by Natera Nurtures, the company’s employee resource group dedicated to com...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera’s oncology testing portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Reco...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in single-gene noninvasive prenatal testing (sgNIPT). Building on the success of the initial Fetal Focus 5-gene test, launched in August, the new expanded p...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 28.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is evaluating a blood-based screening test for the detection of CRC and advanced adenomas (AA). This latest analysis from the U.S. based, prospective PROCEED-CRC clinical trial (NCT06620627) fo...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.10.2025       Natera
US6323071042

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Natera Inc. (NASDAQ: NTRA) breached their fiduciary duties to shareholders. If you currently own Natera stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a c...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The findings demonstrate that Signatera can expand the adjuvant treatment window and guide the use of adjuvant atezolizumab (Tec...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Company’s 2025 Next Big Things in Tech list. Honored for its Signatera personalized molecular residual disease (MRD) test, Natera was one of five companies recognized in the health and medicine category. This annua...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includ...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate includes six oral presentations, reinforcing Natera’s position as a l...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 30.09.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for pat...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.09.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer. Uterine cancer is the m...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc. The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics’...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current stan...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 25.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research. These publications span high-impact journals – such as Natur...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision s...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Signatera ctDNA test in patient...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.08.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San Francisco, CA. The presentations span kidney, heart and lung transplantation and represent one of the most comprehensive coll...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Info...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior t...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.07.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ab...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.07.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~20...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.07.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.06.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer im...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study analyzed the performance of Signatera Genome in a cohort...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.05.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an incr...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.05.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.05.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera’s personalized molecular residual disease (MRD) test, in patients with soft tissue and bone sarcomas. Results of the study (Utilizing Circ...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.05.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.04.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA. DEFINE-HT is the firs...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States. This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 202...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.04.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL. Highlights from AACR include: An oral presentation titled “Large-scale Genomic Pr...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.03.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study i...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.03.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.03.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera’s extensive intellectual property estate, including a strong portfolio o...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.02.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.02.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call In...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.02.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for colon cancer, rectal cancer, and merkel cell carcinoma (MCC). In its upda...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.02.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United States. Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is av...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.01.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink